Immvira Pharma Confirms Participation in BiOPartnering
19 December 2025
Immvira Pharma Confirms Participation in BiOPartnering
According to Frost & Sullivan, the global oncolytic immunotherapy market is projected to grow from USD 87.1 million in 2024 to USD 1.56 billion in 2028, and further expand to USD 17.145 billion by 2033.
Founded in 2015, Immvira Pharma is a globally leading biotech company focused on clinically-driven innovation. The company develops novel oncolytic immunotherapies and engineered exosome therapies using advanced engineering technologies. On June 25, 2025, Immvira officially submitted its listing application to the Hong Kong Stock Exchange. Prior to its IPO, Immvira completed multiple financing rounds, with the latest C+ round in January 2024 reaching a post-money valuation of USD 485 million. Leading investors include Hillhouse Capital, Huagai Capital, Qinzhi Capital, and Angel Capital, among others.
Immvira Pharma @ BIOCHINA2026 BiOPartnering Meetings
Partnership Interests: Seeking opportunities for out-licensing, co-development, and strategic investment.
Key Pipeline Highlights
1. MVR-T3011: Proprietary engineered HSV-1 backbone with high replication capacity, carrying PD-1 antibody and IL-12; mid-dose BCG-unresponsive HR NMIBC Papillary 12-month RFS >70%
2. MVR-C5252: HSV-1 backbone engineered for glioma, carrying PD-1 antibody and IL-12
3. EX103 (Skin Repair): Delivers four functional proteins (EGF, FGF-2, PDGF-BB, KGF); topical application significantly reduces stretch marks
4. EX104 (Hair Growth): Delivers four functional proteins (Wnt10b, KGF, VEGF); topical application increases hair density by ~19% over 90 days
5. EX105 (Localized Fat Reduction): Delivers three functional proteins (FGF-21, IL-27, ActRIIB inhibitor); topical application reduces waist circumference by ~0.85 cm per week
About Immvira Pharma
Immvira Pharma is a globally leading biotech company focused on clinically-driven innovation. Its pipeline includes oncolytic immunotherapies for solid tumors (with bladder cancer as the primary indication) such as MVR-T3011 (Phase II), oncolytic immunotherapies for malignant gliomas such as MVR-C5252 (Phase I), and engineered exosome therapies targeting chronic, refractory, and aging-related diseases. Key exosome candidates include EX103 (Skin Repair), EX104 (Hair Growth), EX105 (Localized Fat Reduction), and EX101 (Wound Healing).